PMGC Capital LLC Urges Alaunos Therapeutics (NASDAQ: TCRT) to Accept Term Sheet from Leading Wall Street Bank Behind Many Leading Crypto Strategies

Biotech Stocks Momentum Decline: Several biotech stocks have experienced significant declines in their Momentum scores over the past week, indicating a loss of strength in the sector.

Key Companies Affected: Notable companies like Capricor Therapeutics, Lava Therapeutics, Alaunos Therapeutics, and Champions Oncology have all reported drops in their Momentum scores due to various factors, including regulatory setbacks, financial losses, and downgrades from analysts.

PMGC Capital's Urging of Alaunos Therapeutics: PMGC Capital LLC has publicly urged Alaunos Therapeutics to accept a financing term sheet facilitated by a leading Wall Street bank, emphasizing that it represents a significant opportunity for the company and its shareholders.

Commitment to Shareholder Value: PMGC Capital remains dedicated to collaborating with Alaunos' leadership to enhance long-term shareholder value while commending the company's prudent financial management during challenging market conditions.

PMGC Capital's Acquisition: PMGC Capital LLC announced its acquisition of 83,500 shares (approximately 5.09%) in Alaunos Therapeutics, indicating a belief that the company is undervalued and has potential for growth.

Strategic Engagement Plans: PMGC Capital intends to engage with Alaunos' management to explore strategic opportunities such as mergers, acquisitions, or partnerships, while commending Alaunos for its financial stewardship.

Earnings Report: Alaunos Therapeutics reported a second quarter 2024 earnings per share of -71 cents and revenue of $4,000.

Automated Coverage: InvestorPlace Earnings utilizes TradeSmith data to automate the reporting of quarterly earnings, providing quick access to key financial figures without human intervention.